FDA Accepts Regeneron (REGN) BLA for Garetosmab Under Priority Review
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best value stocks to buy now.
Regeneron Pharmaceuticals Inc. (REGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AQR Capital Management Cliff Asness | 995,710 | $768,518,494 | +39% | 0.4% |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 604,540 | $466,626,290 | -35% | 0.91% |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 478,551 | $369,379,164 | +24% | 0.34% |
| 4. | Holocene Advisors Brandon Haley | 460,723 | $355,618,262 | +204% | 0.75% |
| 5. | 407,100 | $314,228,277 | +2% | 2.56% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $487.01 | 2,557 | $1,245,286.62 | 23,880,537 | 2017-08-25 | Filing | |
| $485.99 | 2,681 | $1,302,949.65 | 23,877,980 | 2017-08-25 | Filing | |
| $485.28 | 5,723 | $2,777,256.30 | 23,875,299 | 2017-08-25 | Filing | |
| $484.21 | 2,000 | $968,420.00 | 23,869,576 | 2017-08-25 | Filing | |
| $482.87 | 4,485 | $2,165,687.20 | 23,867,576 | 2017-08-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $790.00 | 4 | $3,160.00 | 1,703 | 2026-02-19 | Filing | |
| $785.61 | 56 | $43,994.16 | 1,707 | 2026-02-19 | Filing | |
| $784.45 | 160 | $125,512.00 | 1,763 | 2026-02-19 | Filing | |
| $783.29 | 220 | $172,323.80 | 1,923 | 2026-02-19 | Filing | |
| $782.10 | 298 | $233,065.80 | 2,143 | 2026-02-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,075,153 | $7,004,838,346 | 0.1% | |
| 2. | 8,741,270 | $6,747,123,706 | 0.11% | |
| 3. | 4,660,808 | $3,597,537,871 | 0.12% | |
| 4. | 4,596,358 | $3,547,790,849 | 1.92% | |
| 5. | 3,940,160 | $3,041,292,891 | 0.19% |
News See All
11 Best Value Stocks to Buy Now
On February 7, Richard Bernstein, the CEO of Richard Bernstein Advisors, joined 'The Exchange' on CNBC to discuss the current state of the equity markets and his firm's macro-driven investment strategy...
Here's What Analysts Are Saying About Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best immunotherapy stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc.
12 Best Immunotherapy Stocks to Buy According to Hedge Funds
On February 13, Matt Orton, Raymond James Investment Management's chief market strategist, appeared on CNBC’s ‘The Exchange’ to talk about the recent trends in equity markets and what may drive ...
Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts?
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best medical research stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc.
10 Best Medical Research Stocks to Buy According to Hedge Funds
On January 27, Sarah James, Cantor Fitzgerald analyst, appeared on CNBC’s ‘Squawk on the Street’ to talk about the healthcare insurance sector and the stocks coming under pressure.
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory
We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Notes From The Beauty Contest’s Substack by Crashkolnikov. In this article, we will summarize the bulls’ thesis on REGN.
Regeneron (REGN) Draws Higher Target From TD Cowen
During the Q4 2025 earnings call, CEO Leonard Schleifer said Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) delivered steady revenue growth. Fourth-quarter sales rose 3% from a year earlier.
Regeneron Pharmaceuticals, Inc. (REGN) Posts Q4 Earnings Beat, EPS Shines
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most profitable healthcare stocks to buy. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2025 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2025 Earnings Call Transcript January 30, 2026Regeneron Pharmaceuticals, Inc. beats earnings expectations.
Hedge Fund Resource Center